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Abstract  
 
Purpose: Sleep disordered breathing (SDB) is highly prevalent in older adults. Increasing 
evidence links SDB to the risk of dementia, mediated via a number of pathways, some of 
which may be attenuated by low-dose aspirin. This study will evaluate, in a healthy older 
cohort, the prospective relationship between SDB and cognitive function, changes in retinal 
and cerebral microvasculature, and determine whether low-dose aspirin ameliorates the 
effects of SDB on these outcomes over 3 years.  
 
Design: SNORE-ASA is a sub-study of the ASPirin in Reducing Events in the Elderly (ASPREE) 
randomised, multi-centre, placebo-controlled trial evaluating the effect of daily 100mg aspirin 
on disability-free and dementia-free survival in the healthy older adult aged 70 and over. At 
baseline, 1400 ASPREE participants successfully underwent a home sleep study with a home 
sleep study screening device for SDB; and 296 underwent 1.5 Tesla brain magnetic resonance 
imaging (MRI) and retinal vascular imaging (RVI). Cognitive testing, brain MRI and RVI is 
being repeated after 3 years.  
 
Primary outcome measures: Change in the modified mini-mental state examination score. 
Secondary outcome measures are changes in other cognitive tests, and changes in abnormal 
parameters on RVI and volume of white matter hyper-intensities on brain MRI.   
 
Conclusion: Identifying preventive therapies for delaying the onset of dementia is of 
paramount importance. The results of this study will help clarify the impact of the SDB on risk 
of cognitive decline and cerebral small vessel disease, and whether low-dose aspirin can 
ameliorate cognitive decline in the setting of SDB.  
 
Keywords: Sleep Disordered Breathing, Dementia, Cognitive Decline, Low-dose Aspirin, Brain 
Magnetic Resonance Imaging, Retinal Vascular Imaging 
 
SNORE-ASA Trial Registration: ACTRN12612000891820 
The Principal ASPREE study is registered with the International Standardized Randomized 
Controlled Trials Register, ASPirin in Reducing Events in the Elderly, Number: 
ISRCTN83772183 and clinicaltrials.gov NumberNCT01038583 
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1. Introduction  
 
Sleep disordered breathing (SDB) is highly prevalent in older adults1. Most SDB is 
asymptomatic and undetected, and its clinical significance is uncertain2-4. Emerging evidence, 
however, suggests SDB may be a risk factor for cognitive decline and dementia5-8. SDB may 
increase the risk of cognitive decline via the potential intermediary effects of systemic 
hypertension, inflammation, endothelial dysfunction, and platelet hyper-reactivity on cerebral 
small vessel disease (SVD)9-12. Some of these pathways and effects may be responsive to 
aspirin therapy. This paper discusses the rationale and methodology of the Study of Neuro-
cognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea (SNORE-ASA), 
a sub-study of the larger ASPirin in Reducing Events in the Elderly (ASPREE) trial13.  
 
2. Rationale for the SNORE-ASA study 
 
2.1 Growing Burden of Dementia  
 
Dementia is a leading cause of disability and death globally in the setting of ageing 
populations14. Despite significant investment into clinical trials, to date no disease-modifying 
agent is available. This underpins the imperative to identify and implement preventive 
strategies for both cognitive decline and dementia. Several risk factors for dementia, apart 
from age and family history, have been well-established including hypertension, diabetes, 
physical inactivity and smoking and collectively such risk factors have been estimated to 
contribute to nearly 50% of all prevalent Alzheimer’s dementia cases 15. Trials investigating 
the modification of singular or multiple risk factors on cognitive outcomes are of current 
interest16.  In this context, sleep disorders have recently emerged as another possible, and 
modifiable, risk factor for cognitive decline and dementia in older adults, with perhaps the 
most robust evidence existing for SDB5. 
 
 
2.2 Sleep Disordered Breathing (SDB)  
 
2.2.1 Sleep Disordered Breathing in Older Adults 
 
SDB refers to changes in respiration that occur during sleep. Obstructive Sleep Apnea (OSA) is 
by far the most common sub-type, and occurs when temporary obstructions in the upper 
airway occur during sleep, leading to an intermittent reduction (hypopnea) or complete 
cessation (apnea) in respiration. Physiological sequelae include large intra-thoracic pressure 
swings and intermittent hypoxemia, associated with sympathetic activation, endothelial 
dysfunction and hypertension17. Clinical outcomes of atrial fibrillation, stroke, cardiovascular 
and renal disease as well as mortality have been found to be associated with OSA in middle -
aged populations18. OSA also causes multiple, imperceptible arousals from sleep, with 
resultant daytime sleepiness and reduced quality of life. Furthermore, in middle-aged adults 
untreated OSA has been associated with cognitive dysfunction, in particular in the domains of 
attention, psychomotor speed and executive function 19. 
 
In older age, OSA becomes more prevalent, with community-based studies reporting a 
prevalence of OSA, of at least moderate severity, in 7-53% of adults aged over 701-3,5,20. The 
increased prevalence in older adults may reflect age-related changes in upper airway muscle 
tone, as well as weight, medication use and co-morbid conditions 21. The majority of OSA in 
older adults is undetected, frequently asymptomatic3, and its clinical significance is not firmly 
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established. A growing body of evidence, however, suggests SDB may be a risk factor for 
dementia in older adults5-8.  
 
2.2.2.  Mechanisms by which SDB may contribute to risk of dementia in older adults 
 
SDB has been postulated to contribute to the risk of cognitive decline and neuro -degeneration 
via a number of mechanisms (see Figure 1). The relationship may in some part be explained 
by intermediaries, such as hypertension, atrial fibrillation and stroke, which are themselves 
complications of untreated SDB, as well as contributors to cognitive decline and dementia. 
 
Figure 1: Possible mechanism via which SDB may potentiate neuro-degeneration 
Legend: WMH- White Matter Hyper-intensities, CMB – Cerebral Microbleeds, BBB – Blood Brain Barrier 
 
SDB itself, however, may potentiate neuro-degeneration independently of these effects, via 
the direct and/or indirect effects of hypoxia, inflammation and sleep fragmentation. Neuronal 
structures, in particular the hippocampus and prefrontal cortex 22,23, are vulnerable to the 
effects of hypoxia as well as oxidative stress24. Hypoxia may play an important role in altering 
the metabolism of amyloid-beta, the pathological hallmark and trigger of Alzheimer’s related 
tauopathy, as suggested by both animal25 and human studies 26.  
 
Intermittent hypoxia also appears to drive localised inflammatory changes (increase in neural 
cytokines and microglial activation) in the hippocampus in animal models 27, as well as 
peripheral activation of inflammatory pathways 28, with inflammation implicated in the 
propagation of Alzheimer’s pathology29.  
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SDB has also been associated with vascular endothelial dysfunction, increased platelet 
reactivity30, and evidence of structural and functional change in intra-cerebral vessels in 
vivo31, whilst SDB indices, particularly of hypoxia, have been prospectively associated with 
prevalence of micro-infarcts and gliosis in an autopsy study32. Several neuroimaging studies 
conducted in both middle and older aged groups have also found an association between OSA 
and measures of cerebral small vessel disease, such as white matter hyper-intensity volume 
and silent brain infarction 12,30,33,34.  
 
Another mechanism by which SDB may impact cognition adversely is by the deleterious 
impacts of sleep deprivation and fragmentation, substantiated by seminal animal studies 
demonstrating the role of sleep in clearing amyloid beta35 and neurotoxins from the 
cerebrospinal fluid 36, as well as studies of  self-reported sleep quality and duration showing 
association with amyloid burden on PET imaging 37,38,  and measured sleep duration 
correlating  with Alzheimer’s pathology at autopsy39. Multiple observational studies have also 
found prospective relationships between poor sleep quality (both self-reported and measured 
with actigraphy) and incident cognitive decline and dementia. 
 
As further evidence of the link between SDB and neuro-degeneration, OSA has also been 
associated with localised changes on MRI in gray matter volume40,41, brain metabolites42 and 
abnormalities of white matter tracts as revealed by Diffusion Tensor Imaging (DTI)43 
including use of Fractional Anisotropy (FA)43,44.  
 
2.2.3. Evidence of a relationship between SDB and Dementia 
 
Several epidemiological studies of older populations lend increasing weight to SDB as a risk 
factor for cognitive decline and dementia.. The most compelling longitudinal study was 
conducted in elderly women aged 82 at baseline and followed for nearly 5 years, in whom the 
presence of SDB of at least moderate severity was associated with an adjusted odds ratio (OR) 
of developing MCI or dementia of 1.85 (confidence interval [CI] 1.11-3.08) over the follow-up 
period5. A similar odds ratio has been found for the risk of developing dementia within 5 
years of an OSA diagnosis in a larger Taiwanese population database6.  Individuals with 
untreated SDB reported a diagnosis of MCI, and AD, approximately 10 and 5 years 
respectively before individuals without SDB in an analysis of the large Alzheimer’s Disease 
Neuroimaging Initiative7. Several studies have found the relationships between SDB indices 
and cognitive outcomes were strongest for measures of hypoxia, compared with those for 
measures of sleep fragmentation5,8,45. In contrast, two large population based studies with 
cognitive measures conducted 846 and 1547 years after a sleep study found no, or only mild, 
associations between baseline SDB measures and cognitive function, although survival bias 
may have impacted these results. A recent meta-analysis of six prospective studies evaluating 
the relationship between SDB and cognitive decline reported a risk ratio of 1.26 (CI 1.05-1.50) 
for the outcome of cognitive impairment48. A summary of relevant studies evaluating these 
relationships are presented in Tables A and B in the Appendix.  
 
2.3 Preventing Cognitive Decline in the setting of SDB 
 
2.3.1 Effect of CPAP on Cognitive outcomes in SBD 
 
Continuous Positive Airway Pressure (CPAP) is the first line treatment for symptomatic OSA, 
providing benefits in improving daytime sleepiness and quality of life 49, and modest effects on 
blood pressure control50 and glycaemic profile51. Observational studies have suggested CPAP 
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may improve cognitive function in older adults with OSA52 and in those with MCI or 
dementia53,54. 
 
The role of CPAP for improvement of OSA-associated cognitive dysfunction has been 
evaluated in middle-aged adults with improvements in some domains observed55, although a 
large, randomised and sham-controlled trial of CPAP therapy in more than 1000 middle-aged 
adults with clinically diagnosed OSA reported no significant difference in cognitive outcomes 
between the CPAP and sham arms after 6 months of follow-up56. The role of CPAP in 
preventing cognitive decline or dementia in older adults merits investigation. A large RCT of 
CPAP for older patients with an average age of 71 and with outcomes reported after 3 and 12 
months of therapy, examined change in cognition as a secondary outcome. No difference was 
reported between the two arms (although the study was not powered to assess this outcome 
adequately)57. 
 
A limitation of CPAP for older adults is adherence. Randomised controlled trials such as those 
described above report low adherence to CPAP therapy amongst participants. In older adults 
with co-morbidities, including cognitive impairment, and given that SDB in older adults is 
common and commonly asymptomatic, the adherence to CPAP might be expected to be worse. 
Thus, alternative interventions that may mitigate the impact of SDB on cognitive outcomes 
warrant investigation.  
 
2.3.2 The Potential of Low Dose Aspirin in the setting of SDB 
 
Low-dose aspirin is a widely available and reasonably well-tolerated medication, with a well-
established role in the secondary prevention of cardiovascular and cerebrovascular disease58.  
Aspirin has both anti-inflammatory and anti-thrombotic actions, each of which has the 
potential to confer benefit in the setting of SDB with respect to cognitive outcomes. 
 
The role of low-dose aspirin in the prevention of cognitive decline and dementia is under 
investigation through the principal ASPREE trial13, and while results from existing, largely 
observational data are unfavourable59, low-dose aspirin may confer greater benefits on 
cognitive outcomes in populations with higher baseline risk factors60.  In the setting of SDB, 
older adults with a higher baseline risk of stroke, cerebral small vessel disease and 
inflammation may derive such a greater benefit from low-dose aspirin. Low-dose aspirin 
therapy may therefore, via its anti-thrombotic effects and/or by reducing inflammation, play a 
role in slowing cerebral small vessel disease. This in turn may reduce the incidence of 
moderate to severe cerebral small vessel disease, silent brain infarction (SBI) and stroke, all 
associated with increased risk of cognitive decline.  
 
Conversely, low-dose aspirin poses small risks of major intracranial and gastrointestinal 
bleeding, and the effects of low-dose aspirin on cognitive outcomes in the setting of SDB may 
be small. However, given the high prevalence of SDB in older adults, the population effects of 
low-dose aspirin on cognitive outcomes could be significant, and the presence of SDB may 
represent a sub-group in which a greater benefit of low dose aspirin exists.  
 
2.3.3 Evaluating the effect of aspirin on cognitive outcomes and the potential of retinal 
vascular imaging  
 
Retinal vessels offer a unique, and efficient, non-invasive window to assess cerebral vascular 
health in vivo61,62. Quantitative assessment of retinal vessel calibre (diameter), branching 
structure, and other retinopathy changes (e.g.. microaneurysms), have been applied to 
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various ocular and systemic disease assessments, with relationships found between these 
retinal vessel changes and risk of clinical stroke63, lacunar stroke64, SBI and WMH65,66. Retinal 
arteriolar narrowing may reflect cumulative small vessel damage from the effects of ageing, 
and hypertension and has been linked with endothelial dysfunction while retinal venular 
dilatation has been linked with inflammation67. Both predict incident stroke. Prior studies 
have also demonstrated that retinal vascular imaging (RVI) changes can predict the 
development of a range of disorders including hypertension, diabetes, stroke and coronary 
heart disease.68,69 Retinal vascular calibre changes have also been associated with cognitive 
impairment in general70 and diabetic populations71 and with Alzheimer’s disease72.  
 
The relationship between SDB and RVI changes has been evaluated in a few studies. In one 
cross-sectional analysis of younger adults, no association was found73. In two other studies of 
middle and older aged participants, associations between SDB and retinal arteriolar diameter 
were found, although associations differed based on gender74,75. However, the relationship 
between SDB and RVI has not been evaluated prospectively, nor the impact of low-dose 
aspirin on these relationships. Associations have also been found between SDB and ocular 
diseases such as glaucoma76,77, diabetic retinopathy78 and diabetic macular oedema79, perhaps 
mediated by alterations in ocular blood flow due to SDB. In addition to brain MRI, therefore, 
RVI provides another sensitive modality with which to investigate the impact of SDB on 
cognition, and the effects of low-dose aspirin on brain vascular pathology. 
 
2.4 The aims and objectives of the SNORE-ASA trial 
 
The SNORE-ASA study aims to determine the effects of SDB on cognition and measures of 
cerebral small vessel ischemia in a healthy elderly population over three years of follow-up, 
and whether daily low-dose aspirin alters cognitive decline associated with SDB. 
Overall hypothesis: SDB impairs cognition in the elderly, mediated in part by cerebral 
microvascular changes that can be attenuated by low-dose aspirin. The presence of SDB 
identifies an elderly population in which low dose aspirin is particularly effective in reducing 
cognitive decline.  
 
Specific Hypotheses 
1. A) The presence of moderate/severe SDB at baseline is associated with poorer 
cognitive performance (within normal range) at baseline, and  
B) A steeper decline in cognition across 3 years of follow-up.  
C) The severity of SDB (none/mild/moderate/severe) will correlate with baseline 
cognitive performance and the gradient of decline. 
2. A) The severity of SDB at baseline will correlate with baseline levels of RVI 
abnormalities (as a reflection of central nervous system (CNS) microvascular 
disease) and with baseline CNS vascular changes on brain MRI.  
B) The severity of SDB at baseline will correlate with rate of accumulation of RVI 
and MRI changes. 
C) RVI and MRI changes will correlate with cognitive performance. 
3. Low-dose aspirin reduces the rate of progression of cognitive decline, and this 
beneficial effect will be greater in those with moderate/severe SDB. 
 
4. Low-dose aspirin reduces the rate of development of RVI changes and extent of 
MRI changes, and this reduction will be proportionately greater in those with 
moderate/ severe SDB.   
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Materials and Methods 
 
3.1 Study Design 
 
This study is a randomised, placebo controlled multicentre trial of low dose aspirin (100mg) 
conducted in healthy adults aged 70 and over, residing in Australia, and followed for 3 years. 
SNORE-ASA is a sub-study of the ASPREE trial.  
 
3.2.1 The ASPREE Principal Trial 
ASPREE is a multi-centre, randomized, double-blinded, placebo-controlled trial of daily, low 
dose aspirin being conducted in 19,114 healthy community dwelling older adults in the USA 
and Australia, of which 16703 were recruited from Australia. In Australia the age eligibility 
was 70 years and over 13.  ASPREE is a primary prevention study and will determine whether 
100mg aspirin daily extends disability-free and dementia- free survival in the elderly.  
The ASPREE study methods have been described in detail elsewhere 13. In brief, the majority 
of Australian ASPREE participants have been recruited through partnerships with general 
practitioner (GP) co-investigators. A small proportion was recruited from direct community 
promotion.  
Inclusion and exclusion criteria for the principal ASPREE study have been published 
elsewhere and are summarised in the first two columns of Table 1.  
Participants meeting initial ASPREE eligibility at a screening study visit were given a four 
week placebo run in. A compliance check was performed at the second baseline study visit 
four weeks later. Randomization of study drug followed a block randomization procedure and 
was stratified by site and age (65-79y and >80y) using the Stata ‘ralloc’ procedure. 
Participants were randomized to receive either 100mg of enteric coated aspirin or an enteric 
coated placebo, which are identical in appearance, in a ratio of 1:1. A 12 month supply of 
study medication was dispensed and is thereafter at each annual visit. Study participants, 
investigators and general practitioner co-investigators remain blind to allocation.  
ASPREE participants have face-to-face study visits annually. Contact is made via telephone at 
3 monthly intervals in between. The 6 month phone call ascertains additional information 
relevant to study endpoints. The ASPREE study began in 2010, completed recruitment in 
December 2014 (16,703 in Australia and 2,411 in the USA) and will conclude in 2017.  
The primary endpoint is a composite of death or dementia (adjudicated according to the DSM-
IV criteria) or persistent loss of the same Katz ADL. Pre-specified secondary endpoints include 
death, cardiovascular and cerebrovascular disease, cancer, cognitive impairment, depression, 
physical disability and clinically significant bleeding. Independent committees, who are 
provided with de-identified clinical information about the event, adjudicate all clinical 
endpoints. 
 
3.2.2 The SNORE-ASA Study 
Participants for the SNORE-ASA sub-study are a sub-group of ASPREE Australian participants. 
The inclusion criteria for the SNORE-ASA sub-study are identical to those for ASPREE. 
Additional exclusion criteria specific for SNORE-ASA were a known diagnosis of OSA, or 
current use of a CPAP device, as SNORE-ASA is focusing on the natural history and impact of 
low-dose aspirin on previously undetected and untreated SDB (see column 3 on Table 1). 
Participants in SNORE-ASA were recruited from March 2012 until December 2014.  
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Table 1: Exclusion and Inclusion criteria for the ASPREE, SNORE-ASA and SNORE-ASA 
imaging subset. 
 
ASPREE  
(Australia only) 
   
 
SNORE-ASA 
 
SNORE-ASA 
Imaging  
Inclusion criteria Exclusion Criteria Additional Exclusion 
Criteria 
Additional exclusion 
criteria 
 
Able to give 
informed consent 
 
Able to attend a 
study visit 
 
Aged 70 and above 
 
Established CVD* 
Atrial Fibrillation 
Dementia 
Score <78 on 3MSt 
Disability 
Anaemia 
High risk of recurrent 
bleeding 
Condition likely to 
cause death within 5 
years 
Current use of aspirin 
or another 
antithrombotic agent 
Uncontrolled 
Hypertension 
 
Current use of aspirin/ 
other antiplatelet 
agent for secondary 
prevention 
 
 
Known diagnosis of OSA 
 
Current use of CPAP 
 
 
Cardiac pacemaker 
 
Cochlear implant 
Retained metal 
fragment in the eye  
 
Non-compatible 
cerebral-aneurysm 
clip. 
Legend: *CVD- Cardiovascular disease, tModified mini-mental state examination 
 
We aimed to invite a sub-group of 365 SNORE-ASA participants with access to Alfred Hospital 
imaging facilities in Melbourne to undergo brain MRI and RVI (see column 4 of Table 1 for 
additional exclusion criteria).  
 
Consent and ethics approval 
ASPREE participants provided separate consent for the SNORE-ASA study at their second 
baseline ASPREE visit. SNORE-ASA has specific ethics approval from the Alfred Health Human 
Research Ethics Committee (primary body), and the following committees as secondary 
approval sites: Monash University Human Research Ethics Committee, ACT Health Human 
Research Ethics Committee and the Human Research Ethics Committee University of 
Adelaide. 
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3.3.1 Measures and Timeline  
Participants in SNORE-ASA have relevant assessments performed at study entry and at year 3. 
Assessments at baseline included cognitive function testing, completion of questionnaires 
assessing daytime sleepiness and a home sleep study (see Table 3 for timeline of ASPREE 
principal trial and SNORE-ASA specific measures). Cognitive function testing is repeated at 
year 3.  
 
Before study medication was commenced, a sub-set of participants underwent a brain MRI 
and RVI. Both measures have, or will be, repeated at year three. 
 
Measures specific to the SNORE-ASA study are detailed below: 
3.3.2 Sleep Disordered Breathing (SDB) and Daytime Sleepiness: 
SDB was assessed at study entry using an Apnealink Plus device (Resmed Inc, Sydney, 
Australia) that participants wore overnight in their own home.  Instructions on how to use 
the device were provided by study staff at the second ASPREE baseline visit.  Participants 
were encouraged to complete the sleep study at their earliest convenience and return the 
device in a reply-paid envelope.   
 
The Apnealink Plus device is a single chamber unit that measures nasal airflow and snoring 
via nasal prongs, and has been validated for use at home compared with the gold standard of 
‘in hospital’ polysomnography80.  The device does not measure sleep. Respiratory effort is 
measured by a pneumatic strain gauge and oxygen saturation is measured using a pulse 
oximeter. It provides measures of the Apnea-Hypopnea Index (AHI) and oxygenation 
desaturation index (ODI) and can distinguish between obstructive and central sleep apnoea. 
The AHI reported by the ApneaLink Plus is based on nasal flow and total recording time. The 
AHI (which is usually based upon full polysomnography) refers to a measure of the number 
of apneas and hypopneas occurring each hour during sleep. An AHI <5 is considered normal. 
An AHI of 5-15 is considered to represent mild SDB, 15-30 represents moderate SDB and 
>30 severe SDB. The ODI is a measure of the frequency of a drop in oxygen saturation of 3% 
from the baseline level. Similar to the scale for the AHI, an ODI of < 5 is normal, 5-15 
represents mild, 15-30 moderate, and >30 severe SDB. Both measures have high diagnostic 
utility for moderate or severe OSA, however technical failure is lower with oximetry making 
the ODI a more robust measure81,82. 
 
On return of the device, the digitised output was uploaded to a central database, and one of 
three sleep physician investigators reviewed the raw and composite data from each sleep 
study. For inclusion into the study for analysis, a minimum of 4 hours of recording of 
oximetry was required and the trace had to be free of significant artefact.  
 
A report on the sleep study, including a grading of SDB as normal, mild, moderate or severe, 
was provided in a letter and sent to each participant’s GP. This letter was provided even if 
the recording was less than 4 hours.  Participants completed two questionnaires at home to 
measure daytime sleepiness- the Epworth Sleepiness Scale (ESS) and the Functional 
Outcomes of Sleep Questionnaire (FOSQ). Both are very widely used in the sleep field, and 
well-validated83,84. The ESS measures sleepiness over the preceding month and the FOSQ is a 
broader sleep-related quality of life instrument. These were returned along with the home 
sleep study, and the results of these questionnaires further informed the reports on the 
sleep studies to GPs. Participants also returned a short questionnaire designed for this study  
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Table 2: Study Timeline 
Measurement Recruitment 
& Screening 
Assessment 
& Eligibility 
Annual 
Review 
Annual 
Review 
Annual 
Review 
Year - 4 weeks 0 year 1 year 2 years 3 years 
 ASPREE Study 
Inclusion/ Exclusion criteria & Consent X     
Demographics and Lifestyle factorsa X  X X X 
Blood Pressure and Heart Rate  X  X X X 
Weight, waist circumference and 
height* 
 X X X X 
Cardiovascular Biomarkersb X     
Cognitive Function  Xc Xd Xcd  Xcd 
Clinical Event Recording X X X X X 
Compliance check   Xt X X X 
Study medication Dispensed 
(annually) 
Xt  X X X X 
 SNORE-ASA 
Inclusion/ Exclusion Criteria & Consent  X    
Home Sleep Study  X    
Sleep Questionnairese  X    
Brain MRI and RVIf  X   X 
Additional Cognitive Testsg  X   X 
 Legend: aMedical history & medications, smoking and alcohol history, level of education, first 
language; bincludes haemoglobin, creatinine, urine spot albumin, LDL, cholesterol and fasting 
glucose; c 3MS, dHVLT-R, COWAT-F, SDMT and CES-D-10; e ESS and FOSQ; f for a sub-set of 357 
participants; g Stroop test and Color Trails Test; *height at baseline only; t placebo  
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on the overall quality of sleep (good, average, poor), approximate time of sleep and duration 
of sleep the night the device was worn. 
 
Treatment of SDB: Participants have been free to pursue treatment of any SDB identified, if 
deemed appropriate by their treating GP or physician. Reports back to participants’ GPs 
outlined the uncertain significance of SDB in older adults, particular ly for those without 
excessive daytime sleepiness. Information on any CPAP therapy or other sleep apnoea 
treatment initiated after the sleep study is collected at Year 3 by study staff at the annual 
study face to face visit. It is anticipated only a minority of participants identified with 
moderate/severe SDB will choose to go on to commence CPAP.  
 
3.3.3 Cognitive Function 
Cognition was assessed at the baseline study visits on study entry, and is again at year 3, by 
research staff trained and certified to deliver the tests in a standardised manner.  The 
cognitive function tests assess four key domains– see Table 4 for domains and tests utilised. 
 
Table 3: Cognitive domains assessed and tests used 
Cognitive Domain Tests 
General Cognition Modified Mini-mental State Examination (3MS)- a 
score of >77 required for study eligibility 
Attention/ processing speed Symbol Digit Modalities Test, Color Trails A* 
Memory Hopkins Verbal Learning Test- Revised: 3-trial 
immediate recall; delayed recall; recognition 
discrimination index 
Executive Functioning Controlled Oral Word Association Test (COWAT)-F , 
Color Trails interference index*; Stroop Colour-word 
time*; Stroop Colour-word errors* 
Cognitive testing is performed as part of principal ASPREE study. 
* Indicates Tests additional for SNORE-ASA participants 
 
3.3.4.  Brain Imaging  
A sub-set of 297 participants underwent a brain MRI at study entry (before study 
medication was dispensed) and have done or will do so again at 3 years. This sub-set was a 
convenience sample of participants living in proximity to the imaging facility at the Alfred 
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Hospital in Melbourne. The MRI is acquired on a 1.5 Tesla Siemens Scanner. Several MRI 
sequences are used to assess various aspects of the subject’s brain commencing with a 
sagittal T1 localiser scan. FLAIR images are used to assess deep white matter 
hyperintensities. Axial T1 and T2 images are then acquired to assess brain structure and 
volumes, followed by a coronal Gradient Echo image to ascertain the presence of cerebral 
microbleeds and finally by an ASL (Arterial Spin Labelling) and associated EPI T2 scan that 
allows a determination of blood flow in the cerebral structures. 
 
MRI Imaging Protocol: 
Tri-pilot + FLAIR ; T1 + T2 (Myelography T2 at 256 x 256 x 256). Measurements: WMH – Total 
volume of WMH, as well as deep white matter and periventricular WMH volumes separately 
are calculated; SBIs- the presence or absence of sub-cortical infarction as well as total volume 
will be measured. Also, the presence and count of cerebral microbleeds as well as whole brain 
and ventricular volumes are assessed. 
 
MRI Analyses – All analyses of MRI are performed at the Centre for Advanced Imaging, The 
University of Queensland using automated processing pipelines. Pre-processing for all 
volumetric images follows best practice that has been developed for such studies with large 
numbers of participants85. This includes: (1) N3 B0 MRI nonlinear intensity distortion 
correction, between scan intensity normalisation, registration to a population specific model 
that is then later matched to the ICBM model of cortical anatomy; (2) Model-based 
segmentations of whole brain, ventricular, lobar and hippocampal volumes; (3) WM/GM 
segmentation – a multi-spectral segmentation utilising all the acquired data types provide a 
good measure of the CSF and WM/GM volumes, and consequently, accurate atrophy measures 
as well as lobar WM/GM differences; (4) Nonlinearly register the EPI T2 from the functional 
scans to the gradient echo (GE) volumetric T2. The GE T2 is then be matched to the 
volumetric T1 and then to the ICBM model using an iterative nonlinear registration algorithm.  
 
3.3.5 Retinal Vascular Imaging  
Retinal photography – 311participants underwent standardized non-mydriatic retinal 
photography at baseline. This included 296 of the 297 participants who underwent MRI, and a 
further 15 participants whose MRI was not completed due to claustrophobia, contra-
indication or other technical difficulty. After 5 minutes of dark adaptation, colour retinal 
photographs were taken without pharmacological pupil dilation using Canon NMR 45 digital 
fundus cameras.  
 
Two retinal photographs centred on the optic disc (ETDRS standard field 1) and macula 
(standard field 2), respectively, were taken from both eyes of each consented participant. The 
retinal photography took between 10 and 15 minutes. 
 
Retinal vasculature assessment - The photographs are sent to the Centre for Eye Research 
Australia (CERA) in Melbourne for analysis by assessors blinded to treatment allocation. 
Photographs centred on the optic disc of each eye are examined using standard computer -
assisted retinal analysis software that was developed for the Atherosclerosis Risk In 
Communities study86. The grading approach measures retinal vessel diameters and combines 
the measurements into central retinal artery and vein equivalents with formulas adjusting for 
branching, following the Parr and Hubbard formulae later modified by Knudtson 87 et al. This 
software has now been modified and improved and used in a number of studies, including the 
AusDiab and the Blue Mountains Eye studies in Australia69,88.  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
In brief, using a semi-automated system the graders measure the calibres of arterioles and 
venules crossing a zone defined as the region from ½ to 1 disc diameter from the optic disc. 
The grader carefully corrects any misclassification of vessel type, selects appropriate ve ssel 
regions for calibre measurement according to a standardised protocol, and ensures the largest 
six arterioles and venules have been included by the software, adding them in if necessary. 
The calibre of the six largest arteriole and venules are summarised into the central retinal 
artery equivalent (CRAE) and central retinal venule equivalent (CRVE) respectively as per the 
formula proposed by Knudtson et al87.   
 
The qualitative presence of focal retinal arteriolar narrowing, arteriovenous nicking, 
arteriolar wall opacity and the presence of retinopathy lesions are assessed subjectively. Each 
lesion is classified as definite, questionable, or absent across the two retinal photographic 
fields. The grading is performed by trained retinal image graders at CERA with supervision 
and adjudication provided by ophthalmologists. Inter- and intra-grader reliability is assessed 
in a sub-sample of images. 
 
3.4.1 Study Outcomes 
The primary outcome will be cognitive decline as measured by progressively lower scores 
on the 3MS at 3 years.  
 
Secondary outcomes will be retinal vascular changes over 3 years and volume of WMH and 
SBI on MRI at 3 years, as well as incident cognitive impairment (exclusive of dementia), as 
defined by a fall in summed averaged z-scores of > 1 SD on any cognitive domain within 3 
years. 
 
3.5 Statistical analysis 
3.5.1 Sample Size and Study Power 
The initial sample size calculation, in 2012, was based on an expected prevalence of 
moderate/severe OSA of 40% of people at this age1 and a conservative estimate of the effect 
of SDB on cognitive outcomes, based on a paucity of longitudinal data available on the 
relationship between SDB and cognitive outcomes, and an estimated standard deviation (SD) 
in cross-sectional 3MS scores of 5. Allowing for 5% loss to follow-up, recruiting 3,300 people 
for the SNORE-ASA trial was estimated to provide 80% power (2-sided α 0.05) to detect an 
aspirin/SDB interaction with a mean within-person 3 year 3MS change of -2.5 and -1.0 
points/100 for placebo and aspirin groups with SDB respectively, and -0.5 and 0 for placebo 
and aspirin groups without SDB respectively, assuming an SD of 5 in each group for within-
person 3 year changes in the 3MS.  
 
In 2014, with recruitment well advanced, it was clear that the attained recruitment would be 
substantially less. However, in the setting of accumulating evidence of a more substantial 
effect of SDB on incident cognitive decline5,6,89, and the observed SD of the 3MS score in the 
larger ASPREE study cohort being found to be 4.34 points/100 in the >3000 ASPREE 
participants who had been followed to 3 years by mid-2014, the sample size target was 
revised. Allowing for 5% loss to follow-up and approximately 95% having reasonable sleep 
studies then recruiting 1,500 people for the SNORE-ASA trial provides 80% power (2-sided 
α= 0.05) to detect an aspirin/SDB interaction anticipating mean 3 year 3MS changes of -3.8 
and -2.0 points/100 for placebo and aspirin groups with SDB, respectively, and -0.5 and 0 
points/100 for placebo and aspirin groups without SDB respectively, assuming a Standard 
Deviation of 4.34 in each treatment group on 3 year changes in the 3MS.  Our final recruited 
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number of participants completing a sleep study was 1578, of whom 1400 had sleep studies 
of at least 4 hours of recording and free of significant artifact, and forms the final cohort.  
 
For the MRI/RVI sub-study 365 participants would provide 80% power to detect a 3 year 3MS 
change with SDB that is 0.32 SD lower, a small to moderate effect size, than without SDB (2-
tailed α = 0.05), allowing for a 10% prevalence of ungradable RVI. The achieved samples of 
297 MRI and 311 RVI give approximately 72% power to detect this 3 year 3MS change. 
Further, these sample sizes give 80% power to detect a correlation coefficient of 0.15 based 
on a two-sided p value cut-off of 0.05 for statistical significance, i.e. small effect sizes can be 
detected in the other analyses relating CNS vascular changes and cognitive change implied in 
hypothesis 2 (See Table 4, below). 
 
Table 4: Hypotheses and Power Calculations 
 
Hypothesis Power Calculation 
Low-dose aspirin reduces the rate of 
progression of cognitive decline, and this 
beneficial effect will be greater in those with 
moderate/severe SDB over 3 years 
1,500 people provides 80% power (2-sided α= 
0.05) to detect an aspirin/SDB interaction 
anticipating mean 3 year within-person 3MS 
changes of -3.8 and -2.0 points/100 for placebo 
and aspirin groups with SDB, respectively, and -
0.5 and 0 points/100 for placebo and aspirin 
groups without SDB respectively, assuming a 
standard deviation of 4.34 in each treatment 
group for 3 year within-person changes in 3MS 
scores.   
Severity of SDB at baseline correlates with rate 
of accumulation of RVI and MRI changes over 3 
years. 
 
365 participants would provide 80% power to 
detect a mean 3 year within-person 3MS 
change with SDB that is 0.32 SD lower, a small 
to moderate effect size, than without SDB (2-
tailed α = 0.05), allowing for a 10% prevalence 
of ungradable RVI.  
 
 
3.5.2 Statistical analysis  
 
Descriptive statistics of baseline characteristics will be tabulated. Relevant univariable 
analyses will be used as a starting point for subsequent confirmatory analyses relating to each 
hypothesis.  
Baseline values of 3MS score, RVI abnormalities, WMH, and SBI will be analyzed with linear 
regression models that include one of the explanatory variables: presence or absence of sleep 
apnea or severity of SDB (none/mild/moderate/severe) to address the cross-sectional 
aspects of hypotheses 1 and 2. Changes over 3 years in the same outcomes (3MS, MRI and 
RVI) will be analyzed using analysis of covariance (ANCOVA), i.e. assessing how change in the 
outcome relates to SDB or (for RVI and MRI) baseline cognition or rate of cognitive decline to 
address the longitudinal aspects of hypotheses 1 and 2. The same analyses with explanatory 
variables expanded to include the interaction of SDB and aspirin/placebo assignment will 
address hypotheses 3 and 4.  
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Continuous variables will be log transformed  where their distribution is observed to be 
positive skewed. Further analyses will adjust in the regression models for age, gender, 
hypertension, cholesterol level, BMI, and diabetes. These additional analyses would have a 
dual purpose: to provide insight into possible mechanisms of disease incidence and 
progression, and to improve precision in estimated associations of interest for the  study 
hypotheses. Incident cognitive impairment (exclusive of dementia) as defined by a fall in 
summed averaged z-scores of > 1 SD on any cognitive domain (see above) will also be an 
outcome of interest and will be analyzed using logistic regression models. 
 
4. Discussion 
 
SDB is highly prevalent in healthy older populations, yet in the majority it is largely 
undetected. The clinical significance of asymptomatic SDB in the elderly is yet to be fully 
established, and the findings of several studies linking SDB to incident cognitive decline and 
dementia warrant replication in a well-designed prospective study of a representative cohort 
of older adults.  Further information on the mechanisms via which SDB may potentiate neuro -
degeneration is also needed.  
 
The SNORE-ASA study will add valuable data on the prospective relationship between SDB 
and incident cognitive decline in an older cohort, and on associations of SDB with 
neuroimaging and retinal biomarkers of vascular disease. Moreover, studies on the treatment 
of SDB to date have focused on devices, such as CPAP, for treatment, and while effective in 
managing symptomatic SDB (i.e. in improving daytime sleepiness), CPAP may not be effective 
in reducing all complications associated with SDB, including cardiovascular90 and cognitive 
outcomes57. Moreover, CPAP may be less acceptable to an older population, particularly if the 
SDB itself is asymptomatic.  
 
Conversely, low-dose aspirin is relatively well tolerated and likely to facilitate better 
compliance. Low-dose aspirin, through antiplatelet and anti-inflammatory effects may modify 
vascular changes associated with SDB and have a role in protecting against cognitive decline 
and dementia, although possible adverse effects of aspirin to exaggerate bleeding must 
counter this. The role of aspirin in primary prevention to extend physical disability-free and 
dementia-free survival is being evaluated in the principal ASPREE study. Aspirin may confer 
greater absolute risk reduction in older adults with a higher baseline risk of dementia and 
cognitive impairment, such as may be present in those with SDB. The results of this sub-study 
will help determine whether the presence of SDB defines a sub-group who will derive a 
greater benefit on cognitive outcomes from aspirin therapy. Furthermore, even if the effect of 
aspirin on cognitive decline in the elderly with SDB is small, given the high prevalence of SDB 
in the elderly, the potential for a population effect is important.  
 
The principal ASPREE study infrastructure, recruitment model, depth of data variables 
obtained, and processes for retention of a healthy elderly population have facilitated the 
development of numerous sub-studies that can explore a number of common ageing-related 
conditions and their interaction with low-dose aspirin. This is a particularly efficient model 
which adds significant value to the ASPREE trial, and which will help to identify those healthy 
older adults for whom differential risk:benefit profiles of low-dose aspirin for primary 
prevention exist. The SNORE-ASA sub-study design poses some limitations, including a study 
cohort that are relatively healthy at baseline and free of established cardiovascular disease, as 
well as free of those with prior diagnoses of OSA. Moreover, while the Apnealink Plus sleep 
study device facilitated participation of a large group of older adults across a wide geographic 
area, it cannot provide data on sleep duration, sleep fragmentation and sleep stages.  
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However, despite this, the results of the SNORE-ASA, expected in late 2018, are likely to be of 
interest. First, the study will help to establish, in a cohort of healthy elderly, whether SDB is a 
risk factor for incident cognitive decline over time. Second, by utilising brain MRI and RVI at 
two time points in a sub-set, it will investigate the impact of SDB on cerebral small vessel 
disease and its relationship with cognitive impairment. Third, it will investigate whether  an 
affordable, relatively well-tolerated and convenient medication – aspirin - can ameliorate 
deleterious effects of SDB in the elderly. Finally, the collection of sleep study data from the 
SNORE-ASA trial, combined with data from the principal ASPREE study (including 
cardiovascular endpoints) and other sub-studies (including those dedicated to neuroimaging, 
depression, falls and fractures, vision and hearing loss) provides for future hypothesis-
generating research through post-hoc analysis, including a differential effect of aspirin on 
cardiovascular outcomes in the setting of SDB. 
 
5. Conclusion 
 
SDB is common in older adults, often undetected and asymptomatic. A growing evidence base 
links SDB to an increased risk of cognitive decline and dementia. This may be mediated in part 
through the effects of intermittent hypoxemia on cerebral vasculature. CPAP has not yet been 
soundly established as effective in the prevention of cognitive decline and dementia in the 
setting of SDB in older adults and suffers from poor compliance. Aspirin, by contrast, may 
attenuate some of the mechanisms via which SDB impacts cognitive outcomes, and is 
reasonably well tolerated. The SNORE-ASA study will provide further valuable data on the 
clinical significance of SDB in older adults, and evaluate whether aspirin plays a role in 
moderating cognitive outcomes attributable to SDB in this age group.  
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Appendix 
 
Table A: Community-based, longitudinal studies evaluating relationship between SDB 
in older adults and cognitive outcomes 
 
 
Study 
and 
Year 
Population Measure of 
SDB 
SDB 
Prevalence 
Cognitive Measures Follow-
up 
Duration 
Results 
Quan 
et al, 
200691 
147 men 
and women, 
mean age 
57, no 
history of 
CPAP for 
OSA  
 
Unattended 
home PSG  
N/A – case 
control 
WAIS-III Picture 
Completion, Digit Span, 
Letter-number 
sequencing, Digit Symbol 
Coding, Symbol Search 
sub-sets, Stroop Color 
and Word Test, Trail-
making test, Grooved 
Pegboard 
Mean 24 
months 
(9-40 
months) 
after PSG 
No differences 
in any 
cognitive test 
between OSA 
and no OSA 
group. Reduced 
motor speed 
associated with 
O2 sat <85% 
Yaffe 
et al, 
20115 
298 women, 
mean age 
82  
Unattended 
home PSG 
32.5% with 
AHI ≥15 
3MS, California Verbal 
Learning Test, Digit Span, 
category and verbal 
fluency tests, Trails B. 
DSM-IV for dementia or 
MCI diagnosis 
Mean 4.7 
years 
ODI ≥ 15 
associated with 
1.71 (CI 1.04-
2.83) adjusted 
OR for 
development of 
dementia or 
MCI 
Black
well et 
al, 
20158 
2636 men 
mean age 
76  
Unattended 
home PSG 
43% with 
AHI ≥15 
Trails B, 3MS Mean 3.4 
years 
-0.36 annual 
decline in 100 
point 3MS 
score for each 
5 unit increase 
in ODI 
Martin 
et al, 
201446 
559 men 
and women 
aged 67 
Unattended 
nocturnal 
respiratory 
recording 
72% with 
AHI ≥15 
Trails A and B, Stroop 
Color word, Coding sub-
set of WAIS, semantic 
and categorical fluency, 
Benton Visual Retention 
Test form C, Free and 
Cued Selective 
Reminding Test, MMSE 
Mean 7.8 
years 
SDB measures 
at baseline 
associated with 
mild reduction 
in attention 
tests after 
adjustment 
Lutsey 
et al, 
201647 
966 men 
and women 
mean age 
61  
Unattended 
home PSG 
17.6% with 
AHI ≥15 
Digit Symbol Substitution 
Test, Delayed Word 
Recall Test, Word 
Fluency Test, Trails A 
and B, Digit Span 
Backwards, Logical 
Memory Test, part A; 
Logical 
Memory Test, part B; 
Incidental Learning, digit-
symbol pairs; 
Clock Time Perception. 
Median 
14.9 years 
No association 
of SDB 
measures with 
cognitive 
function 
 
Legend Abbreviations – AHI = Apnea Hypopnea Index, ODI = Oxygen Desaturation Index WAIS = Wechsler 
Adult Intelligence Scale, 3MS = Modified Mini-mental State Examination; PSG = polysomnography; MMSE = 
Mini-mental State Examination 
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Table B: Large cross-sectional studies evaluating relationship between SDB and 
cognitive outcomes in older adults 
 
Study and 
Year 
Population Measures 
and 
prevalence 
of SDB 
Measures of 
Cognition 
Results 
Boland et al, 
200292 
1700 with 
mean age 62.5  
Unattended 
home PSG; 
25% had RDI 
>10% 
Delayed Word Recall 
Test, Digit Symbol 
Subtest (from WAIS-R) 
and first letter Word 
Fluency 
No association 
between cognitive 
function scores and 
RDI; Weak 
relationship 
suggested for severe 
RDI and 
psychomotor speed 
Spira et al, 
200893 
448 women 
mean age 83  
Unattended 
home PSG; 
13% had AHI 
>30, mean 
AHI 15 
MMSE, Trails B All SDB measures 
associated with 
impairment on 
MMSE, (but not on 
Trails B), especially 
for APO4 
Sforza et al, 
20101 
827 men and 
women aged 
68  
Unattended 
home PSG; 
53% with 
AHI >15  
MMSE, Free and cued 
selective reminding 
test, Benton visual 
memory test, digit 
span test, memory 
span and Tracking 
Baddeley dual task, 
Trail Making test A 
and B, Stroop Test, 
alphabetic and 
category fluency test, 
WAIS similarities test  
No association 
between AHI >15 
and any cognitive 
measure; AHI>30 
associated with 
lower score 
immediate recall 
and Stroop 
Haba-Rubio 
et al, 201745 
580 
community 
dwelling men 
and women, 
291 with 
cognitive 
impairment. 
Mean age 72  
Unattended 
home PSG.  
MMSE, Grober and 
Buschke Double 
Memory Test, DO80 
naming test, Stroop, 
letter fluency, CERAD 
figures and Clinical 
Dementia rating scale.  
ODI ≥ 4% and ≥ 6% 
associated with 
presence of 
cognitive 
impairment in 
multivariate 
analysis 
 
Legend. Definitions – RDI = Respiratory Desaturation Index; other abbreviations as defined in 
Table 1  
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